Drugs / Ascorbate

Trials 14

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT04877587 Jan 2023 → May 2025 bone sarcoma, soft tissue sarcoma David Dickens Withdrawn No outcome recorded Stop: Enrollment
Phase 0 NCT04634227 Nov 2020 → Mar 2025 overdue bone sarcoma, soft tissue sarcoma University of Iowa Active not recruiting No outcome recorded
Phase 14 trials
Phase 1 NCT06083454 Oct 2023 → Apr 2025 non-small cell lung carcinoma William Zeitler Terminated No outcome recorded Stop: Business
Phase 1 NCT04900792 Feb 2023 → May 2025 overdue glioblastoma Bryan Allen Active not recruiting No outcome recorded
Phase 1 NCT01852890 Jan 2014 → Jan 2019 pancreatic neoplasm Joseph J. Cullen Completed No outcome recorded
Phase 1 NCT01752491 Apr 2013 → Nov 2015 glioblastoma Joseph J. Cullen, MD, FACS Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03508726 Jun 2019 → Jun 2022 soft tissue sarcoma Mohammed Milhem Completed No outcome recorded
Phase 24 trials
Phase 2 NCT07283900 Mar 2026 → May 2028 expected myelodysplastic syndrome Prajwal Dhakal Recruiting No outcome recorded
Phase 2 NCT03541486 Dec 2025 → Dec 2029 pancreatic neoplasm Joseph J. Cullen, MD, FACS Withdrawn No outcome recorded Stop: Business
Phase 2 NCT06018896 Aug 2023 → Aug 2025 overdue malignant pancreatic neoplasm Fudan University Recruiting No outcome recorded
Phase 2 NCT03468075 Jul 2018 → Apr 2019 bone sarcoma, soft tissue sarcoma Mohammed Milhem, MBBS Terminated No outcome recorded
Phase 31 trial
Phase 3 NCT06018883 Aug 2023 → Aug 2025 overdue pancreatic adenocarcinoma Fudan University Active not recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT00140166 Jul 2005 → May 2008 schizophrenia Beersheva Mental Health Center Completed No outcome recorded
Phase not applicable1 trial
— NCT00434005 Jul 2008 → Aug 2010 — University of Washington Completed No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT02058212 Comparator Mar → Oct 2013 endometriosis Cairo University Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 19 sources stand behind the page.

FieldValueCited text
Known as Ascorbate ClinicalTrials.gov intervention name — accepted as the source's own label NCT03468075 ↗
14

NCT00434005 ↗

NCT07283900 ↗

NCT02058212 ↗

NCT04900792 ↗

NCT01752491 ↗

NCT00140166 ↗

NCT03541486 ↗

NCT04634227 ↗

NCT03508726 ↗

NCT06018883 ↗

Show 4 more sources

Known as ascorbic acid “high-dose, intravenous pharmacological ascorbate (ascorbic acid, vitamin C)” PMID 26201606 ↗ 2015
Known as P-AscH- “Pharmacologic ascorbate (P-AscH-, i.e., intravenous infusions of ascorbic acid, vitamin C), but not oral ascorbate, produces high plasma concentrations capable of selective...” PMID 30254147 ↗ Sep 2018
Known as PAA “Intravenous pharmacologic ascorbic acid (PAA) is one such treatment.” PMID 29438178 ↗ Apr 2018
Known as vitamin C “Durvalumab plus ascorbate (also known as vitamin C), followed by surgical resection of the tumor.” NCT06083454 ↗
Known as VitC “Vitamin C (VitC) is known to directly impair cancer cell growth in preclinical models” PMID 32102933 ↗ Feb 2020
Route Intravenous “administered by IV” NCT01752491 ↗